Array BioPharma, Inc.
3200 Walnut Street
Boulder
Colorado
80301
United States
Tel: 303-381-6600
Fax: 303-381-6697
Website: http://www.arraybiopharma.com/
Email: bd@arraybiopharma.com
467 articles about Array BioPharma, Inc.
-
Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019
2/5/2019
Array BioPharma Inc. (Nasdaq: ARRY) today reported results for its second quarter of fiscal 2019 and provided an update on the progress of its key commercial products and clinical development programs.
-
Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019
1/29/2019
Array BioPharma, Inc. will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019.
-
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
-
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
1/14/2019
Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium
-
Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
12/20/2018
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
-
Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
11/20/2018
Array BioPharma Inc. today announced that its Chief Executive Officer, Ron Squarer, will speak at the 30th Annual Piper Jaffray Healthcare Conference in New York.
-
BioSpace Movers and Shakers Nov. 12
11/12/2018
Biopharma companies name new members of their leadership teams. Who made big moves this week? -
Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference
11/6/2018
Array BioPharma Inc. today announced that its Chief Executive Officer, Ron Squarer, will speak at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference.
-
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
10/30/2018
Strong launch quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $14 million in net sales
-
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018
10/23/2018
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, October 30, 2018.
-
Overall, the Swiss-based Roche announced a group sales increase of 7 percent, with the Pharmaceuticals Division up 7 percent, largely driven by sales of Ocrevus, Perjeta, Alecensa and Tecentriq.
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
9/13/2018
- BRAFTOVI + MEKTOVI demonstrated a median overall survival of 33.6 months in patients with advanced BRAF-mutant melanoma in Phase 3 COLUMBUS trial -
-
ASLAN PHARMACEUTICALS TO PRESENT AT HC WAINWRIGHT 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE
9/4/2018
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation at the HC Wainwright 20th Annual Global Investment Conference.
-
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
8/14/2018
FDA approved BRAFTOVI™ (encorafenib) in combination with MEKTOVI® (binimetinib) for advanced BRAF-mutant melanoma
-
Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors
8/10/2018
Array BioPharma, Inc. today announced that Carrie S. Cox has been named Chairman of its Board of Directors, effective immediately.
-
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
8/7/2018
Array BioPharma, Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib.
-
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018
8/7/2018
Array BioPharma Inc. will report financial results for the fourth quarter and full year of fiscal 2018 and hold a conference call to discuss those results on Tuesday, August 14, 2018. Ron Squarer, Chief Executive Officer, will lead the call.
-
BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
7/27/2018
Positive CHMP opinion is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival
-
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.